Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.10 USD
Change Today +1.10 / 11.00%
Volume 2.8K
VSTA On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

vistagen therapeutics inc (VSTA) Snapshot

Open
$10.50
Previous Close
$10.00
Day High
$11.75
Day Low
$10.50
52 Week High
06/19/15 - $16.50
52 Week Low
02/19/15 - $3.16
Market Cap
17.7M
Average Volume 10 Days
1.5K
EPS TTM
$-8.76
Shares Outstanding
1.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VISTAGEN THERAPEUTICS INC (VSTA)

Related News

No related news articles were found.

vistagen therapeutics inc (VSTA) Related Businessweek News

No Related Businessweek News Found

vistagen therapeutics inc (VSTA) Details

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes products for patients with depression, and other diseases and disorders related to the central nervous system; and cancer. The company’s principal product candidate is AV-101, an orally-active small molecule prodrug, which is in Phase II development for major depressive disorder. It is also involved in the development of CardioSafe 3D, an in vitro bioassay system for predicting potential cardiotoxicity of new chemical entities (NCEs), including drug rescue NCEs; and LiverSafe 3D, a bioassay system to predict potential liver toxicity of new drug candidates, including potential drug metabolism issues and adverse drug-drug interactions. The company has strategic collaborations with University Health Network for hPSC technology research and development; Synterys, Inc. to design, produce, and analyze drug rescue NCEs; and Cato Research, Ltd. for regulatory expertise and clinical development support. It also has cooperative research and development agreement with the U.S. National Institute of Mental Health for the Phase II clinical study of AV-101. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

9 Employees
Last Reported Date: 06/29/15
Founded in 1998

vistagen therapeutics inc (VSTA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $347.5K
Founder, President, Chief Scientific Officer ...
Total Annual Compensation: $305.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2015.

vistagen therapeutics inc (VSTA) Key Developments

Vistagen Therapeutics, Inc. Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study of Orally Active AV-101 in Major Depressive Disorder

VistaGen Therapeutics, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) and the U.S. National Institutes of Health (NIH) to initiate an NIH-funded Phase 2 clinical study of its orally active AV-101 in subjects with treatment-resistant Major Depressive Disorder (MDD) under protocol number 15-M-0151. The Phase 2 study will be a randomized, double-blind, placebo-controlled, crossover clinical trial conducted at the NIMH and designed to evaluate the efficacy and safety of a single oral dose of AV-101 administered once per day for 14 days to approximately 25 patients with MDD. VistaGen and the NIMH expect to initiate enrollment of subjects in the study in third quarter of 2015. AV-101 is an orally active, clinical-stage prodrug candidate that readily gains access to the central nervous system (CNS) after systemic administration and is rapidly converted in vivo to its active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized, potent, and highly-selective antagonist of the glycine-binding co-agonist (GlyB) site of the N-methyl-D-aspartate receptor (NMDAR). Current evidence suggests that AV-101’s antagonism of NMDAR signaling may provide fast-acting antidepressant effects in the treatment of MDD. In addition, as confirmed in two Phase 1 clinical studies, using AV-101 to target the GlyB site of the NMDAR may bypass potential adverse effects that occur with ketamine, while activating similar pathways resulting in the “glutamate surge” that has been associated with increased neurogenesis and the rapid-acting antidepressant effects of ketamine observed in previous clinical studies.

VistaGen Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

VistaGen Therapeutics, Inc. filed its 10-K on Jun 29, 2015 for the period ending Mar 31, 2015. In this report its auditor, Odenberg Ullakko Muranishi & Co LLP - OUM & Co LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

VistaGen Therapeutics, Inc. and U.S. National Institutes of Health Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

VistaGen Therapeutics, Inc. has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Under the CRADA, VistaGen and the NIMH will collaborate on an NIH-sponsored Phase 2 clinical study of AV-101, VistaGen's orally-active NMDA receptor modulator, in subjects with Major Depressive Disorder (MDD). MDD is a widespread and debilitating mental disorder affecting millions worldwide, including nearly 7% of U.S. adults. Dr. Carlos Zarate, Chief of the Section on the Neurobiology and Treatment of Mood Disorders and Chief of the Experimental Therapeutics and Pathophysiology Branch at the NIMH, will be the Principal Investigator of the NIH-funded study, which will be a randomized, double-blind, placebo-controlled, crossover Phase 2 clinical trial designed to evaluate the efficacy and safety of a single oral dose of AV-101 administered once per day for 14 days to approximately 25 subjects with MDD. The primary efficacy measure will be the Hamilton Depression Rating Scale (HDRS), a standard scale for measuring depression severity. VistaGen and the NIH anticipate completing the study in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSTA:US $11.10 USD +1.10

VSTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSTA.
View Industry Companies
 

Industry Analysis

VSTA

Industry Average

Valuation VSTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VISTAGEN THERAPEUTICS INC, please visit www.vistagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.